Trinity生物技术在艾滋病毒检测销售增加和900万TrinScreen测试的主要订单的推动下,在2025年的Q3成果上表现得更加强劲。 Trinity Biotech posted stronger Q3 2025 results, driven by increased HIV test sales and a major order for 9 million TrinScreen tests.

Trinity生物技术公司报告说,2025年的Q3成果更强劲,收入为1 430万美元,其驱动因素是UniGold艾滋病毒测试销售增加,以及根据世卫组织核准的新的外包模式恢复TrinScreen生产。 Trinity Biotech reported stronger Q3 2025 results with $14.3 million in revenue, driven by increased sales of UniGold HIV tests and resumed TrinScreen production under a new WHO-approved outsourcing model. 利润毛额增至650万美元,差值增至45.2%,经调整的欧洲双边投资条约正数为50万美元,反映了其转型计划的进展。 Gross profit rose to $6.5 million, margin improved to 45.2%, and adjusted EBITDA turned positive at $0.5 million, reflecting progress under its transformation plan. 保证了900万个TrinScreen测试的主要订单,将于2025年底和2026年初完成,标志着全球艾滋病毒检测需求恢复。 A major order for 9 million TrinScreen tests was secured, to be fulfilled in late 2025 and early 2026, signaling recovery in global HIV testing demand. 尽管净损失510万美元,但该公司指出,效率和管道进展有所改善,包括新诊断和国际市场扩张。 Despite a net loss of $5.1 million, the company cited improved efficiency and pipeline advancements, including new diagnostics and international market expansion.